Anchor Capital Advisors LLC Sells 50,883 Shares of Eton Pharmaceuticals, Inc. $ETON

Anchor Capital Advisors LLC lessened its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 58.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 36,778 shares of the company’s stock after selling 50,883 shares during the quarter. Anchor Capital Advisors LLC’s holdings in Eton Pharmaceuticals were worth $799,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Opaleye Management Inc. raised its holdings in Eton Pharmaceuticals by 0.3% during the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock worth $40,755,000 after purchasing an additional 7,930 shares during the last quarter. EcoR1 Capital LLC boosted its stake in shares of Eton Pharmaceuticals by 2.0% in the 2nd quarter. EcoR1 Capital LLC now owns 2,030,544 shares of the company’s stock valued at $28,935,000 after purchasing an additional 40,756 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Eton Pharmaceuticals by 98.8% during the 2nd quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock worth $8,450,000 after buying an additional 294,617 shares during the period. Divisadero Street Capital Management LP bought a new stake in shares of Eton Pharmaceuticals during the second quarter worth approximately $7,092,000. Finally, Millennium Management LLC lifted its holdings in Eton Pharmaceuticals by 156.3% in the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after buying an additional 217,042 shares during the period. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Down 1.2%

NASDAQ:ETON opened at $15.17 on Thursday. Eton Pharmaceuticals, Inc. has a 1 year low of $11.09 and a 1 year high of $23.00. The stock has a 50-day moving average price of $16.28 and a two-hundred day moving average price of $17.02. The stock has a market cap of $406.86 million, a price-to-earnings ratio of -60.68 and a beta of 1.18. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 1.19.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.20). Eton Pharmaceuticals had a negative return on equity of 11.32% and a negative net margin of 9.50%.The business had revenue of $22.46 million for the quarter, compared to analyst estimates of $20.47 million. As a group, equities analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on ETON shares. Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wall Street Zen downgraded Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $29.67.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.